 2014 Financial Guidance Conference Call January 7, 2014 Exhibit 99.1 |
 1 Forward-looking Statements Note 1: The guidance in this presentation is only effective as of the date given, January 7, 2014, and will not be updated or affirmed unless and until the Company publicly announces updated or affirmed guidance. Forward-looking Statements Non-GAAP Information Certain statements made in this presentation may constitute forward-looking statements, including, but not limited to, statements regarding preliminary results and guidance with respect to expected revenues, non-GAAP cash earnings per share, adjusted cash flows from operations, organic product sales growth, integration-related activities and benefits, synergies, launches and approvals of products, assumptions with respect to 2014 guidance, and the 2014 strategic initiatives of Valeant Pharmaceuticals International, Inc. (the “Company”). Forward-looking statements may be identified by the use of the words “anticipates,” “expects,” “intends,” “plans,” “could,” “should,” “would,” “may,” “will,” “believes,” “estimates,” “potential,” or “continue” and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the company's most recent annual or quarterly report filed with the Securities and Exchange Commission ("SEC") and other risks and uncertainties detailed from time to time in the Company's filings with the SEC and the Canadian Securities Administrators ("CSA"), which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. The Company undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this presentation or to reflect actual outcomes. To supplement the financial measures prepared in accordance with generally accepted accounting principles (GAAP), the Company uses non-GAAP financial measures that exclude certain items. Management uses non-GAAP financial measures internally for strategic decision making, forecasting future results and evaluating current performance. By disclosing non-GAAP financial measures, management intends to provide investors with a meaningful, consistent comparison of the Company’s core operating results and trends for the periods presented. Non-GAAP financial measures are not prepared in accordance with GAAP; therefore, the information is not necessarily comparable to other companies and should be considered as a supplement to, not a substitute for, or superior to, the corresponding measures calculated in accordance with GAAP. The Company has provided preliminary results and guidance with respect to cash earnings per share, adjusted cash flows from operations and organic product growth rates, which are non-GAAP financial measures. The Company has not provided a reconciliation of these preliminary and forward-looking non-GAAP financial measures due to the difficulty in forecasting and quantifying the exact amount of the items excluded from the non-GAAP financial measures that will be included in the comparable GAAP financial measures. Reconciliations of historical non-GAAP financials can be found at www.valeant.com. |
 2 Agenda 2013 Review – J. Michael Pearson 2014 Priorities – Howard Schiller 2014 Financial Guidance Other Updates – J. Michael Pearson New 2014 Strategic Initiatives |
 3 Previous Q4 Guidance Unchanged Fourth Quarter 2013 Guidance Revenue expected to be >$2.0 billion Cash EPS expected to be between $2.05 - $2.10 Adjusted cash flows from operations expected to be greater than $625 million Organic growth, unadjusted, is positive in the fourth quarter, both same store sales and pro forma See Note 1 regarding guidance |
 4 2013 Full Year Performance See Note 1 regarding guidance 2012 As Reported 2013 Guidance Growth Revenue $3.4 billion* $5.7 - $5.9 billion ~60% - 65% Cash EPS $4.14* $6.11 - $6.16 ~35% - 37% Adjusted Cash Flow from Operations $1.2 billion* >$1.8 billion ~50% * Excludes $66 M from divestiture of IDP-111 generic Efudex and $45M Retigabine Milestone. Cash EPS also excludes $.08/share one time Fx gain |
 5 2013 Highlights Operations: Added another significant Specialty platform – Eye Health Achieved nearly $2.0 billion sales in Emerging Markets Significantly expanded our aesthetic business in U.S. & Canada MVP Program Completed plant consolidations in Brazil, Mexico and Canada Returned U.S. Neuro & Other to growth Business Development: Completed over 25 transactions Bausch + Lomb, Euvipharm (Vietnam), Natur Produkt, Obagi, Majority between 1.5-3 x sales Established new growth platforms China, Eye Health, Middle East, Turkey, U.S. generics, Vietnam Added scale to a number of priority businesses Brazil, Medical Devices, U.S. OTC, Russia, South East Asia Acquired significant number of pipeline/launch products Bensal, Biotrue ONEDay for Presbyopia, BV Metrogel, Luzu, Neotensil (partnership with Living Proof), Peroxiclear, PureVision2 Multifocal for Presbyopia, Trulign IOL, Zeus Balance Sheet Management: Raised $10.7 billion in capital, including both debt and equity |
 6 2013 Highlights (continued) Strengthened Senior Management Team: Dr. Ari Kellen - Company Group Chairman Laizer Kornwasser - Company Group Chairman Dan Wechsler – Company Group Chairman Tom Appio, GM, North Asia Muhittin Bilgutay – GM Turkey, MENA Andy Chang – Sales & Marketing, Surgical Angelo Conti – U.S. Manufacturing Craig Dashefsky – U.S. Commercial Operations Dr. Richard D’Souza – R&D, Eye Health Joe Gordon – U.S. Consumer Kym Hampton – GM, South Africa Deb Jorn – Sales/Marketing Rx Derm Jacques Lacomb – EU Manufacturing Linda LaGorga - Treasurer Ray Larwood – Sales, Eye Health Pharma Dr. Calvin Roberts, CMO, Eye Health Dr. Baldo Sforzolini – Medical/Clinical, Eye Health Tracy Valorie – Marketing, Eye Health Pharma Gaelle Waltinger – GM, Western Europe |
 7 2013 Achievements Average Growth 2009 - 2012 Y/Y Growth 2013 Revenue 65% 64% Cash EPS 30% 36% Total Shareholder Return 64% 96% |
 8 Agenda 2013 Review – J. Michael Pearson 2014 Priorities – Howard Schiller 2014 Financial Guidance Other Updates – J. Michael Pearson New 2014 Strategic Initiatives |
 9 2014 Priorities Continue Strong Organic Growth All business units are expected to have positive growth in 2014 Business units expected to grow double digit in 2014 Aesthetics Consumer Contact Lens Neurology & Other Ophthalmic Rx Oral Health Significant sales force expansions Aesthetics – 94 reps going to ~200 Oral Health – 100 reps going to ~150 New Launches planned Aesthetics – Emervel, Neotensil, Small Particle Hyaluronic Acid for the Lips (SPHAL) Derm Rx – Bensal, CeraVe Baby Line, Jublia, Luzu Eye Health – BioTrue ONEday for Presbyopia, enVista Inserter, Peroxiclear, Victus Fragmentation, Zeus Branded generic launches >300 Asia Central and Eastern Europe Latin America Middle East / N. Africa |
 10 2014 Expected Product Launches Product Business Unit Description Estimated Launch Date Bensal Derm Rx Topical treatment for the inflammation and irritation associated with many forms of dermatitis Q1 CeraVe Baby Line Consumer OTC Moisturizer Q1 Luzu Derm Rx Topical antifungal approved for tinea cruris, corporis, and pedis Q1 Neotensil Aesthetics Topical product that reduces the appearance of under-eye bags within one hour Q1 Jublia Derm Rx Topical antifungal for onychomycosis 2H 2014 (pending FDA approval) enVista Inserter Surgical Latest enhancements enVista inserter Jan/Feb approval and Q1 launch Trulign ranges Surgical Broader range of powers Q2 BioTrue Oneday for Presbyopia Contact Lens Daily Contact Lens Launching regionally in 2014 Peroxiclear Consumer New hydrogen peroxide-based contact lens solution Q2 Zeus Contact Lens Silicon Hydrogel monthly disposable contact lenses Q2 Victus Enhancements Surgical Launch of multiple VICTUS enhancements FDA corneal incision clearance estimated 1H of 2014 / FDA lens fragmentation estimated 2H of 2014 Hyaluronic Acid for Lips Aesthetics Small-particle filler Q4 2014 Emervel Aesthetics Facial injectable filler line Q4 2014/Q1 2015 |
 11 2014 Priorities (continued) Complete Bausch + Lomb Integration Achieve >$850 million run rate synergies by year end Synergy capture to accelerate 2H 2014 due to heavy R&D spend 1H and European Workers’ Council process Maintain double digit organic growth Launch Key Products Continue and/or complete Bausch + Lomb R&D projects Brimonidine Phase 3 (Eye Whitener) Latanoprostene bunod Phase 3 (glaucoma) Lotemax Gel Next Generation (post op inflammation) MIM-D3 Phase 3 (Dry Eye) Zeus Toric & Multifocal contact lens Continue to pursue Value Added Business Development with Tuck-In Acquisitions Continue to be opportunistic Focus on Emerging markets – especially Middle East, Asia and Russia Continue to pursue value added Merger of Equals (MOE) Reduce leverage ratio to less than 4x adjusted pro forma EBITDA |
 12 2014 Guidance Assumptions Planned impact from generics to be >$200m in revenues vs. 2013 to hurt organic growth, particularly Q1 and Q2 Atralin, Lotemax suspension, Retin A Micro, Vanos, Wellbutrin XL (Canada), Zovirax, ~$50m negative total revenue impact from divestitures Includes Solta Expected to close in January No other acquisitions included in guidance Jublia (efinaconazole) U.S. approval expected 2H 2014 Potential launch to be breakeven Gross Margins expected to be in low 70’s Cash Flow Items Cap Ex - ~$200m Depreciation - ~$150m Stock Based Comp - ~$75m |
 13 2014 Guidance Assumptions (continued) Cash EPS expected to be 40% / 60% 1H vs. 2H Q1 expected to be lowest quarter; Q4 expected to be highest quarter Completion of late stage R&D programs ~$200m spend expected in 1H out of $300m total 2014 R&D spend Expected synergy capture of >$850 million run rate by year end to accelerate 2H 2014 due to heavy R&D spend 1H and European Workers’ Council process Net realized annual synergies projected to be at least $650 million Launch costs from Luzu, Neotensil, Zeus Expansion of Oral Health and Aesthetics sales forces; revenue expected to accelerate in 2H Cash tax rate expected <5% Leverage reduced to <4x adjusted pro forma EBITDA by the end of year |
 14 Financial Guidance for 2014 See Note 1 regarding guidance 2014 % over 2013 Revenue ~40% Cash EPS ~40% Adjusted Cash Flow from Operations ~40% $8.25 - $8.75 $2.4 - $2.6 billion $8.2 - $8.6 billion |
 15 Agenda 2012 Review – J. Michael Pearson 2014 Priorities – Howard Schiller 2014 Financial Guidance Other Updates – J. Michael Pearson New 2014 Strategic Initiatives |
 16 New 2014 Strategic Initiatives 1. Achieve Bausch + Lomb annual run-rate synergies of greater than $900 million. 2. Successfully launch key new products – Bensal, Jublia, Luzu, Neotensil, PeroxiClear, Zeus. 3. Build out high priority businesses in Middle East, Russia/CIS, and South East Asia. 4. Reduce leverage ratio below 4x. 5. Do at least one significant deal that creates substantial shareholder value. 6. Become one of the 5 most valuable pharma companies (as measured by Market Cap) by the end of 2016. |
 2014 Financial Guidance Conference Call January 7, 2014 |